ReviewNature reviews. Clinical oncology2015
Advances in umbilical cord blood manipulation-from niche to bedside.
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 75 citations in OpenAlex.
- GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.Bone marrow transplantation · 2017Trial
- Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.Haematologica · 2016Trial
- Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.Cell stem cell · 2016Trial
- VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.Blood advances · 2026Article
- Body Fluid-Derived Stem Cells: Powering Innovative, Less-Invasive Cell Therapies.International journal of molecular sciences · 2025Review
- Enhanced engraftment of human haematopoietic stem cells via mechanical remodelling mediated by the corticotropin-releasing hormone.Nature biomedical engineering · 2025Article
- Restoring mitochondrial function promotes hematopoietic reconstitution from cord blood following cryopreservation-related functional decline.The Journal of clinical investigation · 2025Article
- Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.Nature reviews. Clinical oncology · 2025Review
- Advances in ex vivo expansion of hematopoietic stem and progenitor cells for clinical applications.Frontiers in bioengineering and biotechnology · 2024Review
- Expansion of human hematopoietic stem cells by inhibiting translation.bioRxiv : the preprint server for biology · 2023Article
- Mesenchymal Stromal Cells from Perinatal Tissues as an Alternative for Ex Vivo Expansion of Hematopoietic Progenitor and Stem Cells from Umbilical Cord Blood.International journal of molecular sciences · 2023Article
- Evolving therapies in neuronopathic LSDs: opportunities and challenges.Metabolic brain disease · 2022Review
- Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement.Stem cells translational medicine · 2022Review
- Transient Inhibition of the JNK Pathway Promotes Human Hematopoietic Stem Cell Quiescence and Engraftment.Stem cells translational medicine · 2022Article
- R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling.Blood advances · 2021Article
- An irradiated marrow niche reveals a small noncollagenous protein mediator of homing, dermatopontin.Blood advances · 2021Article
- Natural estrogens enhance the engraftment of human hematopoietic stem and progenitor cells in immunodeficient mice.Haematologica · 2021Article
- Comparative engraftment and clonality of macaque HSPCs expanded on human umbilical vein endothelial cells versus non-expanded cells.Molecular therapy. Methods & clinical development · 2021Article
- Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171.Blood · 2020Article
- Clinical Advancement and Challenges ofClinical hematology international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The use of umbilical cord blood (UCB) as an alternative haematopoietic cell source in lieu of bone marrow for haematopoietic reconstitution is increasingly becoming a mainstay treatment for both malignant and nonmalignant diseases, as most individuals will have at least one available, suitably HLA-matched unit of blood. The principal limitation of UCB is the low and finite number of haematopoietic stem and progenitor cells (HSPC) relative to the number found in a typical bone marrow or mobilized peripheral blood allograft, which leads to prolonged engraftment times. In an attempt to overcome this obstacle, strategies that are often based on native processes occurring in the bone marrow microenvironment or 'niche' have been developed with the goal of accelerating UCB engraftment. In broad terms, the two main approaches have been either to expand UCB HSPC ex vivo before transplantation, or to modulate HSPC functionality to increase the efficiency of HSPC homing to the bone marrow niche after transplant both of which enhance the biological activities of the engrafted HSPC. Several early phase clinical trials of these approaches have reported promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.